Table 2.
Utility and cost values
| Variable | Base-case value (range) | Source |
| Utility | ||
| Event-free (standard strategy) | 0.680 (0.544–0.816) | 16 |
| Event-free (cinacalcet strategy) | 0.646 (0.517–0.775) | 16 |
| Cardiovascular event (acute effect) | 0.324 (0.259–0.389) | 16 |
| Cardiovascular event (chronic effect) | 0.535 (0.428–0.642) | 16 |
| Bone fracture (acute effect) | 0.319 (0.255–0.383) | 16 |
| Bone fracture (chronic effect) | 0.581 (0.465–0.697) | 16 |
| Parathyroidectomy | 0.605 (0.484–0.726) | 21 |
| Cost (US$) | ||
| Cardiovascular event | 2367(1893–2840)/event | China Health Statistics Yearbook in 2018 |
| Bone fracture | 2136(1709–2563)/event | |
| Parathyroidectomy | 6825(5460–8190)/operation | Clinical estimates |
| Haemodialysis | 3345(2676–4014)/cycle | 2 |
| Cinacalcet | 0.24/mg, 1062(531–1593)/cycle | Zhejiang Pharmaceutical Equipment Purchasing Center |
| Calcium acetate | 1.08/g, 583(389–777)/cycle | |
| Sevelamer | 1.51/g, 488(325–652)/cycle | |
| Lanthanum carbonate | 4.36/g, 882 (588–1177)/cycle | |
| Calcium carbonate | 0.19/g, 50(38–63)/cycle | |